2025-12-29 - Analysis Report
Here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the data provided.

**0. Report Format**

The report is structured as follows:

*   **Summary Statistics:** Basic numbers are presented first.
*   **Analysis:** Interpretation and context are added.

**1. Return Rate Comparison**

*   **Ticker:** JNJ
*   **Company Overview:** Johnson & Johnson is a global healthcare company that develops, manufactures, and sells pharmaceuticals, medical devices, and consumer packaged goods.
*   **JNJ Cumulative Return:** 60.02%
*   **VOO (S&P 500) Cumulative Return:** 103.21%
*   **Divergence:**
    *   Current: -41.8%
    *   Relative Divergence: 28.9%

**Analysis:** JNJ has significantly underperformed the S&P 500 over the tracked period.  The current divergence of -41.8% indicates a substantial difference in cumulative returns. The relative divergence of 28.9% suggests that JNJ's underperformance is closer to its historical minimum divergence compared to the S&P 500.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD    | Alpha   | Beta   | Cap(B) |
|------------|---------|--------|---------|--------|--------|
| 2015-2017  | 26.0%   | 66.8%  | -2.0%   | -0.1   | 336.6  |
| 2016-2018  | 14.0%   | 10.7%  | -1.0%   | 0.1    | 310.9  |
| 2017-2019  | 20.0%   | 71.5%  | -2.0%   | 0.4    | 351.4  |
| 2018-2020  | 19.0%   | 79.2%  | -4.0%   | 0.4    | 379.2  |
| 2019-2021  | 33.0%   | 79.2%  | -14.0%  | 0.5    | 412.2  |
| 2020-2022  | 8.0%    | 79.6%  | 9.0%    | 0.4    | 425.6  |
| 2021-2023  | -19.0%  | 79.6%  | -20.0%  | 0.3    | 377.6  |
| 2022-2024  | -32.0%  | 79.6%  | -53.0%  | 0.3    | 348.4  |
| 2023-2025  | 31.0%   | 79.6%  | -37.0%  | 0.1    | 500.2  |

**Analysis:**

*   **CAGR:**  Compound Annual Growth Rate has fluctuated significantly, showing periods of strong growth and periods of decline.
*   **MDD:** Maximum Drawdown is consistently high, indicating substantial downside risk across these periods.
*   **Alpha:** Alpha is mostly negative, implying that JNJ has generally underperformed its benchmark on a risk-adjusted basis.  The exceptions are 2020-2022.
*   **Beta:** Beta generally ranges from 0.1 to 0.5, indicating that JNJ is less volatile than the market.
*   **Cap(B):** Market capitalization shows overall growth, though it has faced fluctuations.

**2. Recent Stock Price Fluctuations**

*   **Close:** 207.63
*   **Last Market:** Price = 207.63, Previous Close = 207.78, Change = -0.07
*   **5-day SMA:** 206.98
*   **20-day SMA:** 206.68
*   **60-day SMA:** 197.41

**Analysis:** The stock price is slightly decreasing but holding steady. The 5-day and 20-day Simple Moving Averages (SMAs) are very close, suggesting that the short-term trend is relatively flat.  The 60-day SMA is significantly lower, indicating that the longer-term trend has been upward.

**3. RSI, PPO Index Indicators**

*   **MRI:** 1.0 (High Investment Recommended)
*   **RSI:** 59.29
*   **PPO:** -0.34
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)
*   **Recent Relative Divergence Change (20 days):** -5.1 (Decreasing)
*   **Expected Return (%):** -59.0%

**Analysis:**

*   **MRI:** The high MRI score suggests a favorable overall market environment for investment.
*   **RSI:** The RSI of 59.29 indicates that the stock is approaching overbought territory, but is not yet there.
*   **PPO:** The negative PPO suggests a slight downtrend, as the short-term moving average is below the long-term moving average.
*   **Hybrid Signal:** This signal suggests a strong buy with 90% cash allocation, which might seem contradictory given the data. This may reflect that the signal prioritizes safety.
*   **Recent Relative Divergence Change:** The decrease in relative divergence suggests underperformance compared to the S&P 500 over the past 20 days.
*   **Expected Return:** The negative expected return is a significant red flag.  It suggests that, based on the model's analysis, JNJ is projected to underperform significantly compared to the S&P 500 over the next 2+ years.

**4. Recent News & Significant Events**

*   **[2025-12-04] Stock Drops Despite Market Gains:** Indicates potential company-specific issues weighing on the stock.
*   **[2025-12-28] Halts Eczema Trial:** A halted drug trial can negatively impact investor sentiment.
*   **[2025-12-28] Shares Purchased by Avanza Fonder AB:** Institutional buying can be a positive signal, but the impact needs to be assessed relative to overall volume and other news.
*   **[2025-12-27] Opinions on Eczema Drug Trial Halt:** Suggests that the market is closely watching the implications of the trial halt.
*   **[2025-11-21] Shares Surging This Month:** Provides a bit of context before the more recent negative news. The reason for the surge should be further investigated.
*   **[2025-12-25] What to Know Before the Market Opens:** Signifies that the market is anticipating potential catalysts or volatility related to JNJ.

**Analysis:**  The news is a mixed bag, but recent headlines are concerning.  The halted eczema trial is a significant negative, and the stock dropping despite market gains is also a negative sign.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.16)
*   **Target Price (avg/high/low):** 209.29 / 240.00 / 155.00
*   **Recent Rating Changes:** No changes reported.

**Analysis:** While the overall analyst consensus is a "Buy," the average target price is only slightly above the current price. The wide range between the high and low target prices suggests uncertainty among analysts.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2025-10-22 | 2.14 | 23.99 B$      |
| 2025-07-24 | 2.3  | 23.74 B$      |
| 2025-04-23 | 4.57 | 21.89 B$      |
| 2024-10-23 | 1.12 | 22.47 B$      |
| 2025-10-22 | 1.12 | 22.47 B$      |

**Analysis:** EPS has been volatile over the past few quarters. The high EPS number in April 2025 skews the data. Revenue has been increasing.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-09-30 | $23.99B  | 69.56%        |
| 2025-06-30 | $23.74B  | 67.87%        |
| 2025-03-31 | $21.89B  | 66.40%        |
| 2024-12-31 | $22.52B  | 68.35%        |
| 2024-09-30 | $22.47B  | 69.01%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-09-30 | $79.28B   | 6.50%   |
| 2025-06-30 | $78.47B   | 7.06%   |
| 2025-03-31 | $78.11B   | 14.08%  |
| 2024-12-31 | $71.49B   | 4.80%   |
| 2024-09-30 | $70.16B   | 3.84%   |

**Analysis:**

*   **Revenue:** Revenue has been generally increasing, indicating growth.
*   **Profit Margin:** Profit margins are very high and relatively stable.
*   **Equity:** Total Equity has been increasing, suggesting a strengthening financial position.
*   **ROE:** ROE (Return on Equity) is volatile, but shows signs of improvement.

**7. Comprehensive Analysis**

Based on the provided data, here's a summary:

*   **Underperformance:** JNJ has significantly underperformed the S&P 500. The negative expected return is a major concern.
*   **Mixed Signals:** Technical indicators provide mixed signals. RSI is nearing overbought territory, the PPO suggests a downtrend, and the MRI suggests a favorable overall investment climate.
*   **News Concerns:** Recent news regarding the halted eczema trial and stock drops is concerning.
*   **Analyst Divide:** Analyst opinions are generally positive ("Buy"), but target prices vary significantly, reflecting uncertainty.
*   **Financial Strength:** JNJ demonstrates financial strength with increasing revenue, high profit margins, and growing equity.
*   **Recommendation:** The negative expected return coupled with recent negative news necessitates caution. While financial fundamentals appear strong, the underperformance and uncertainty surrounding future growth prospects raise concerns. Additional due diligence is needed before investing.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.